

## MT2023-16: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- unresectable, locally advanced or metastatic solid tumors are considered to express epidermal growth factor receptor (EGFR) - willing to have new biopsy(s) for the study if it is possible - able to care for self and do light work - women of childbearing potential must be willing to use 2 forms of contraception throughout the study, starting at screening through 90 days after the last dose of TAK-186 - Males with partners of childbearing potential must use barrier contraception during the entire study treatment period through 120 days after the last dose of study drug and must not donate sperm during this period. Must also have partner use 2 forms of contraception (see above requirement) - contact study staff for additional study requirements

#### Exclusion Criteria:

- history of known autoimmune disease with some exceptions - major surgery or traumatic injury within 8 weeks before first dose of study drug - unhealed wounds from surgery or injury - serious underlying medical or psychiatric condition that would impair the ability of the participant to consent, receive or tolerate the planned treatment (study staff will review) - women who are pregnant or breast feeding

### Conditions & Interventions

#### Interventions:

Drug: TAK-186

#### Conditions:

Cancer

#### Keywords:

Clinics and Surgery Center (CSC), Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Squamous Cell Cancer of Head and Neck (SCCHN)

### More Information

**Description:** This study will test TAK-186, an antibody that selectively targets EGRF-expressing tumor cells, to see if TAK-186 is safe in patients with unresectable, locally advanced or metastatic cancer.

**Study Contact:** Heather Beckwith - einho003@umn.edu

**Principal Investigator:** Heather Beckwith

#### IRB

**Number:** STUDY00019459

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.